An issue of statistical analysis in controlled multi-centre studies: How shall we weight the centres?

Statistics in Medicine

Volumn 18, Issue 4, 1999, Pages 365-373

  Zhengning, Lin ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DATA ANALYSIS; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; STATISTICAL ANALYSIS;

CONTROLLED CLINICAL TRIALS; DRUG THERAPY; HUMANS; MULTICENTER STUDIES;

EID: 0345320344     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19990228)18:4<365::AID-SIM46>3.0.CO;2-2     Document Type: Article

References (6)

1. Fleiss, J. L. 'Analysis of data from multiclinic trials', Controlled Clinical Trials, 7, 267-275 (1986).
2. Fleiss, J. L. 'Multicenter studies', in The Design and Analysis of Clinical Experiments, Wiley, 1985, pp. 176-185.
3. Goldberg, J. D. and Koury, K. J. 'Design and analysis of multicenter trials', in Berry, D. A. (ed.), Statistical Methodology in the Pharmaceutical Sciences, Marcel Dekker 1990, Chapter 7.
4. Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. 'Documentation of statistical methods', Guideline For The Format and Content of the Clinical and Statistical Sections of New Drug Applications, 1988, pp. 68-71.
5. Senn, S. 'Multi-center trails', in Statistical Issues in Drug Development, Wiley, 1997, pp. 187-206.
6. Källén, A. 'Treatment-by-center interaction: what is the issue?', Drug Information Journal, 31, 927-936 (1997).